Immunogenicity of human interferon-beta-containing pharmaceuticals
- 47 Downloads
Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient’s immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring antihuman IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.
Keywordsmultiple sclerosis immunogenicity interferon-beta neutralizing antibodies titer
Unable to display preview. Download preview PDF.
- 4.WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations (2004) WHO Tech Rep., 924, 35–102.Google Scholar
- 5.Van Beers, M. M. C., and Bardor, M. (2012) Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins, Biotechnol. J., 7, 14731484.Google Scholar
- 10.Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H. P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., Petkau, J., Reder, A. T., Reingold, S. C., Schellekens, H., and Sorensen, P. S. (2010) Recommendations for clinical use of data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis, Lancet Neurol., 9, 740–750.CrossRefPubMedGoogle Scholar
- 11.WHO Expert Committee on Biological Standardization. Thirty-fifth report (1985) World Health Organ. Tech. Rep. Ser., 725, 1–140.Google Scholar
- 12.Deisenhammer, F. (2014) Interferon-beta: neutralizing antibodies, binding antibodies, pharmacokinetics and pharmacodynamics, and clinical outcomes, J. Interferon Cytokine Res., 34, 938–945.Google Scholar
- 15.Meager, A., Dolman, C., Dilger, P., Bird, C., Giovannoni, G., Schellekens, H., Thorpe, R., and Wadhwa, M. (2011) An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products, J. Interferon Cytokine Res., 31, 383–392.CrossRefPubMedGoogle Scholar
- 16.Gneiss, C., Tripp, P., Reichartseder, F., Egg, R., Ehling, R., Lutterotti, A., Khalil, M., Kuenz, B., Mayringer, I., Reindl, M., Berger, T., and Deisenhammer, F. (2006) Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients, Mult. Scler., 12, 731–737.CrossRefPubMedGoogle Scholar